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Early quasars ate like the rest
The giant black hole in the most distant-known quasar, which formed just 750 million years after the Big Bang, complex processing steps needed in other forms of lithography. The authors created photonic lattices (pictured), which manipulate light, with resolution as high as 30 nanometres. They also etched patterns out of silk films to which active materials, such as enzymes, proteins or quantum dots had been added. engulfed matter at the same rate as much younger quasars.
Alberto Moretti of the Brera Astronomical Observatory in Milan, Italy, and his colleagues used the European Space Agency's XMMNewton observatory to study ULAS J1120+0641, a galactic centre that produces huge amounts of radiation powered by a supermassive black hole. They found that its X-ray spectrum, an indication of the rate at which the black hole sucks in matter, was indistinguishable from those of quasars seen later in the life of the Universe. The authors had expected that ULAS J1120+0641 would collect matter at a much higher rate because its mass is 2 billion times that of the Sun. The slow growth rate of the galactic centre raises questions about how it could have reached its huge size so early in the Universe's life.
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failure of another.
In 2009, researchers reported that an experimental HIV vaccine had reduced infection risk by 31%, the only HIV vaccine ever shown to be effective. Two teams have now compared the immune responses of people in that trial, known as RV144, with those of participants in a different trial, VAX003, in which a vaccine did not prevent infection. Georgia Tomaras at Duke University in Durham, North Carolina, and her colleagues found that volunteers in the RV144 trial produced a greater response, in terms of IgG3 antibodies, which recognize a portion of HIV's outer shell, than people in the unsuccessful trial.
Another team, led by Galit Alter at Massachusetts General Hospital, Boston, also found that the differences between the two vaccines may be explained by higher levels of IgG3, and by another antibody called IgG1, in the successful trial. These antibodies might have spurred other immune cells to vanquish cells infected with HIV, both teams conclude. 
